Pharmaceutical

AI-driven virtual CGM data boosts understanding of T1D risks

This study reinforces the significance of intensive glycaemic control and is a paradigm shift in managing the disease and its complications.

Jan 28, 2025 - 06:00
AI-driven virtual CGM data boosts understanding of T1D risks
This study reinforces the significance of intensive glycaemic control and is a paradigm shift in managing the disease and its complications.
Read the original article

Tags:

Previous Article

Stealth faces another hurdle as FDA delays decision on Barth syndrome drug

Next Article

GSK and University of Oxford partner for cancer vaccine research

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Digital twins: A new path to personalised medicine

Digital twins: A new path to personalised medicine

Oct 16, 2024

It’s time to stop treating menopause like a disease, researchers argue in series of Lancet articles

It’s time to stop treating menopause like a disease, re...

Mar 6, 2024

Novo Nordisk to invest $2.3bn to expand Danish manufacturing facilities

Novo Nordisk to invest $2.3bn to expand Danish manufact...

Jun 13, 2023